我要投票 乐普LEPU在医疗器械行业中的票数:659
· 外 推 电 报 ·
2026-01-09 07:24:07 星期五

【乐普LEPU是哪个国家的品牌?】

乐普LEPU是什么牌子?「乐普LEPU」是乐普(北京)医疗器械股份有限公司旗下著名品牌。该品牌发源于北京市,由创始人蒲忠杰在1999-06-11期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力乐普LEPU品牌出海!将品牌入驻外推网,定制乐普LEPU品牌推广信息,可以显著提高乐普LEPU产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

创立于1999年,集产品研发、生产、销售于一体,专业从事植介入诊疗器械及设备领域的医疗产品产业集团,其心血管病植介入诊疗器械在业内颇具影响力

乐普(北京)医疗器械股份有限公司(简称乐普医疗集团)创立于1999年,股份制集团上市公司(股票代码300003),公司销售网络遍布全中国及95个国家和地区,年营业收入46亿元人民币。 通过坚持技术创新、合作共赢的发展之路,乐普医疗集团正努力建立四位一体的心血管全产业链平台型企业。

乐普(北京)医疗器械股份有限公司创立于1999年,总部位于北京市中关村科技园区昌平园。公司是从事冠状动脉药物支架、先心封堵器、心脏瓣膜、造影机等心血管疾病植介入诊疗器械及设备产品研发、生产与销售的中外合资央企控股企业,是2009年在深交所创业板上市的28家企业之一。公司目前拥有国内外8家子公司,产品临床应用覆盖全国1200家以上心脏诊疗中心,已发展成为国内从事的心血管病植介入诊疗器械与设备的医疗产品产业集团。

乐普公司集合了材料、机械、电子、精密加工、临床医学等各类专业人才,拥有一支在产品研发、质量控制、临床验证、市场开拓、企业管理等方面专业的经验丰富的人才队伍。研制开发涵盖:冠心病、结构性心脏病、心脏节律、预先和术后诊断及诊疗设备五大领域的植介入产品,取得了一系列具有国内、国际水平的研究成果。是国内规模较大的也是拥有多种技术特点药物支架产品的制造企业,是亚洲较大的人工心脏瓣膜制造企业,是国内心脏起搏器的先行者,是国内心脏封堵器、血管造影机的市场佼佼者,是国内研制肾动脉射频消融导管的企业。

乐普公司疗创立以来,先后承担了国家发改委高技术产业化示范工程项目、国家科技部863计划发展项目、科技支撑计划项目等几十项国家重大课题。2013年,以乐普公司为依托单位,组建了“国家心脏病植介入诊疗器械及设备工程技术研究中心”,将进一步推动建设国家心脏病植介入诊疗器械及设备技术创新、产业化和人才聚集的平台,攻克一系列行业发展的核心技术和核心工艺,推动我国心脏病植介入医疗事业的迅速发展。我们秉承“以科技的力量,从心点燃生命的光辉”,为广大医护工作者提供更好更强的医疗产品与技术,使更多心血管病患者能够用得上用得起中国自己的医疗技术和产品。


英文翻译:Founded in 1999, it is a medical product industry group integrating product R & D, production and sales, specializing in the field of interventional devices and equipment. Its cardiovascular interventional devices have great influence in the industry. Lepu (Beijing) Medical Devices Co., Ltd. (referred to as Lepu medical group) was founded in 1999. The joint stock group listed company (Stock Code: 300003) )The company's sales network covers all over China and 95 countries and regions, with an annual operating revenue of 4.6 billion yuan. By adhering to the development path of technological innovation and win-win cooperation, Lepu medical group is striving to establish a platform enterprise of four in one cardiovascular industry chain. Lepu (Beijing) medical equipment Co., Ltd. was founded in 1999 and its headquarter is located in Changping Park, Zhongguancun Science and Technology Park, Beijing. The company is a Sino foreign joint-venture state-owned enterprise holding the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine. It is one of the 28 enterprises listed on the growth enterprise market of Shenzhen Stock Exchange in 2009. At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a domestic medical product industry group engaged in cardiovascular interventional diagnosis and treatment equipment and equipment. Lepu company has gathered all kinds of professional talents in materials, machinery, electronics, precision processing, clinical medicine, etc., and has a professional team with rich experience in product research and development, quality control, clinical verification, market development, enterprise management, etc. The research and development covers five fields: coronary heart disease, structural heart disease, heart rhythm, pre and post-operative diagnosis and treatment equipment, and a series of research results with domestic and international level have been achieved. It is a large-scale manufacturing enterprise with a variety of technical characteristics of drug stent products in China, a large artificial heart valve manufacturing enterprise in Asia, a pioneer in domestic cardiac pacemaker, a market leader in domestic cardiac occluder and angiograph, and a domestic enterprise in the research and development of renal artery radiofrequency catheter ablation. Since its establishment, Lepu company has successively undertaken dozens of national major projects, such as the high-tech industrialization demonstration project of the national development and Reform Commission, the 863 program development project of the Ministry of science and technology, and the science and technology support program project. In 2013, with Lepu company as the supporting unit, the "National Center for engineering and technology research of heart disease plant intervention diagnosis and treatment equipment and equipment" was established, which will further promote the construction of a national platform for innovation, industrialization and talent accumulation of heart disease plant intervention diagnosis and treatment equipment and equipment, attack a series of core technologies and core processes for industry development, and promote China's heart disease plant intervention medical affairs The rapid development of the industry. We adhere to the principle of "lighting up the brilliance of life from the heart with the power of science and technology" to provide better and stronger medical products and technologies for medical workers, so that more patients with cardiovascular diseases can use their own medical technologies and products in China.

本文链接: https://www.waitui.com/brand/56660df8a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

宏润建设:股东周美珍计划减持不超0.12%股份

36氪获悉,宏润建设公告,股东周美珍因个人资金需求,计划自公告披露之日起十五个交易日后的三个月内,即2026年1月30日至2026年4月29日,通过集中竞价交易方式减持公司股份不超过150.10万股,占剔除公司回购专用账户股份后总股本的0.12%。减持股份来源:因离婚财产分割、通过非交易过户取得的股份。

2小时前

欧盟反垄断监管机构定于2月10日前就谷歌收购Wiz的交易作出裁决

据欧盟委员会网站公示文件,欧盟反垄断监管机构将于2月10日前裁定,是否批准Alphabet以320亿美元收购网络安全公司Wiz的交易,这也是Alphabet有史以来规模最大的一笔收购。(新浪财经)

2小时前

谱尼测试:股票交易严重异常波动 预计2025年度亏损2亿元-2.5亿元

36氪获悉,谱尼测试公告,公司股票自2025年12月24日至2026年1月8日连续10个交易日内日收盘价格涨幅偏离值累计达到+100%,属于股票交易严重异常波动的情况。公司预计2025年度亏损2亿元到2.5亿元。经核实,公司不存在违反信息公平披露的情形,也无应披露而未披露的重大事项或处于筹划阶段的重大事项。公司提醒广大投资者理性投资,注意投资风险。

2小时前

美股大型科技股盘前涨跌不一,苹果跌超1%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,苹果跌超1%,特斯拉跌0.88%,微软跌0.64%,Meta跌0.43%,奈飞跌0.32%;谷歌涨0.91%,英伟达涨0.31%,亚马逊涨0.23%。

2小时前

热门中概股美股盘前多数下跌,哔哩哔哩涨近3%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,拼多多、百度、爱奇艺跌超1%,京东跌0.72%,阿里巴巴跌0.48%,理想汽车跌0.35%,哔哩哔哩涨近3%,小鹏汽车涨超1%,蔚来涨0.21%。

2小时前

本页详细列出关于乐普LEPU的品牌信息,含品牌所属公司介绍,乐普LEPU所处行业的品牌地位及优势。
咨询